AADI (Aadi Bio) שולי הרווח הגולמי

סמל תאגידי ולוגו של Aadi Bioscience (AADI)

Aadi Bioscience delegates drug manufacturing and testing to external contractors to maintain flexibility. The primary focus is on the academic environment and the development of targeted mTOR inhibitors, where scientists are incentivized by stock options. The consistent performance of partner laboratories confirms the effectiveness of this model. The current gross margin demonstrates financial stability, with the indicator standing at 87.40.

AADI - רווחיות לפי רווח גולמי Aadi Bio בטווח 04.07.2022 - 19.03.2025

פילוחי מדדים פיננסיים ומדדי שוק עבור Aadi Bio (AADI)

- שער מניה ותחזית מחירי מומחים:
- מדדי הערכת שווי שוק של העסק:
הערכת שווי פונדמנטלית:AADI aadibio.com
סחורת הדגל של Aadi Bioscience Inc

Gross margin determines production efficiency by measuring the portion of revenue remaining after direct product creation costs. Stable utilization of biotechnological complexes and the absence of downtime in contract drug manufacturing are reflected in the consolidated gross margin trend for Aadi Bioscience (AADI). Analyzing this metric allows investors to assess the asset's operating profitability and determine the company's fair cost of capital.